ULCERATIVE COLITIS: LABORATORY DIAGNOSTIC CRITERIA
Keywords:
inflammatory bowel disease, ulcerative colitis, Crohn's disease, serological markers, acute-phase reactionAbstract
Ulcerative colitis (UC) and Crohn's disease (CD) are the main forms of inflammatory bowel disease (IBD) in humans. Despite some shared characteristics, these forms can be differentiated based on genetic predisposition, risk factors, as well as clinical, endoscopic, and histological features. Currently, the etiology of CD and UC remains unknown; however, a range of data indicates that CD and, possibly, UC arise from an overly aggressive immune response directed against normal components of the gut microflora. In everyday practice, invasive tests are sometimes used for the diagnosis and treatment of patients with IBD. The diagnosis of UC is based on clinical signs and findings from radiological and endoscopic examinations. There is a need for the use of non-invasive biomarkers. The relationship between serological markers, genotypes, and clinical phenotypes should deepen our understanding of the pathophysiology of UC.
References
Abreu MT. Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease. Inflamm Bowel Dis 2012; 8: 224-226; discussion 223, 224-226 51.
Abreu MT. Serologies in Crohn’s disease: can we change the gray zone to black and white? Gastroenterology 2016; 131: 664-667 49.
Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2014; 20: 318-327 56.
Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2011; 120: 13-20 53.
Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2016; 52: 171-181 44.
Cioffi M, Riegler G, Vietri MT, Pilla P, Caserta L, Carratù R, Sica V, Molinari AM. Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm Bowel Dis 2014; 10: 606-611 47.
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lémann M, Mary JY. A simple biological score for predicting low risk of shortterm relapse in Crohn’s disease. Inflamm Bowel Dis 2016; 12: 551-557 52.
Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2014; 99: 938-945 27.
Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology 2016; 131:366-378 40.
Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2012; 122: 1242-1247 50.
Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, Vlietinck R, Aerts R, Rutgeerts P, Bossuyt X. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2014; 10: 771-777 46.
Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2021; 96: 776-781 28.
Klebl FH, Bataille F, Huy C, Hofstädter F, Schölmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn’s disease. Eur J Gastroenterol Hepatol 2015; 17: 73-77 45.
Lakatos PL, Papp M, Rieder F. Serologic antiglycan antibodies in inflammatory bowel disease. Am J Gastroenterol 2021; 106: 406-412 43.
Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn’s diseaseassociated immune responses to auto- and microbial antigens. Gastroenterology 2012; 123: 689-699 39.
Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 2019; 33 Suppl 3: S158-S173 26.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2022; 380: 1606-1619 1.
Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2017; 13: 2028-2036 36.
Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2017; 13: 1561-1566 33.
Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2016; 101: 2410-2422 34.
Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2013; 17: 19-35 54.
Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior. Inflamm Bowel Dis 2010; 16: 263-274 42.
Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol 2021; 5: 703-716 31.
Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, Pellicano R, Sguazzini C, Pagni R, Rizzetto M, Astegiano M. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2018; 14: 645-651 41.
Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 2015; 128:2020-2028 37.
Van Assche G, Vermeire S, Rutgeerts P. Inflimab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2019; 623 Suppl 1: S17-S25 55.
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2014; 10: 661-665 35.
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2016; 55: 426-431 32.
Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn’s disease-associated I2 sequence and T-cell superantigen. Infect Immun 2012; 70: 6567-6575 38.
